title: Formulation optimization of erythromycin solid lipid nanocarrier using response surface methodology.
abstract: In present work response surface methodology (RSM) using the miscellaneous design model was used to optimize formulations of erythromycin solid lipid nanocarriers (ERY-SLN). Two-factor three level factorial design was considered for optimization. There were three parameters, drug entrapment efficiency (EE), drug loading (DL) percentage, and mean particle size of ERY-SLN, considered for investigating the optimal formulation with respect to two independent variables, including lipid concentration (X1) and surfactant : cosurfactant ratio (X2). The result showed that the optimal ERY-SLN was composed of lipid concentration (X1) 15 mg/mL and surfactant : cosurfactant ratio (X2) 1 : 1 with %EE of 88.40 ± 2.09%, DL of 29.46 ± 0.69%, mean particle size of 153.21 ± 2.31 nm, polydispersity index (PDI) of 0.026 ± 0.008, and zeta potential value of -15.18 ± (-5.53) mV. DSC and TEM study showed that there was no chemical interaction between ERY and lipid (GMS) and the ERY-SLN particles are nonspherical, respectively. The drug release experiments exhibited a sustained release over during 24 h, up to 66.26 ± 2.83%. Accelerated stability studies showed that there was no significant change occurring in the responses after storage condition for a total period of 3 months.
authors.affiliation: University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
authors.forename: Anil Kumar
authors.initials: AK
authors.lastname: Sahu
authors.affiliation: University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
authors.forename: Tekeshwar
authors.identifier: 0000-0001-5897-2759
authors.initials: T
authors.lastname: Kumar
authors.affiliation: University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
authors.forename: Vishal
authors.initials: V
authors.lastname: Jain
mesh_terms: D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D004355:Drug Stability; D004917:Erythromycin / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D013501:Surface-Active Agents / Q000737:chemistry
chemical_list: D004337:Drug Carriers; D008055:Lipids; D013501:Surface-Active Agents; D004917:Erythromycin